干细胞临床研究政策回顾和展望

Review and Prospect of China's Policies for Clinical Stem Cell Research

干细胞研究快速、良性的发展离不开国家的有效治理。本文回顾了中国干细胞临床研究的政策、法律、法规等,讨论为什么这些政策法规无法实现对干细胞临床研究的有效治理。本文指出,自上而下的治理机制在其实施过程中有其局限性,需要引入自下而上的创新性治理机制。两者有机结合才能减少权威体制和有效治理之间的矛盾,促进干细胞临床研究更好的发展。

The rapid and sound development of stem cell research needs effective governance of the state. This article reviews China＇s policies and laws for clinical stem cell research, and discusses why these policies and laws could not lead to effective governance of clinical stem cell research. It points out that the top-down governance mechanisms have their limitations in the process of implementation, and bottom-up innovative governance mechanisms need to be introduced. Combining these two governance mechanisms could reduce the tension between the centralization of authority and effective governance, and promote better development of clinical stem cell research.